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Abstract
Background: Psoriasin has been identified as a gene that is highly expressed in pre-invasive breast
cancer, but is often downregulated with breast cancer progression. It is currently unknown
whether psoriasin influences epithelial cell malignancy directly or by affecting the surrounding
environment. However the protein is found in the nucleus, cytoplasm as well as extracellularly. In
the present study we have sought to identify potential psoriasin-binding proteins and to describe
their expression profile in breast tumors.
Methods: The yeast two-hybrid method was used to identify potential binding partners for
psoriasin. The interaction of psoriasin with RanBPM was confirmed in-vitro by co-
immunoprecipitation. The expression of RanBPM and psoriasin was measured by RT-PCR in a
series of breast cell lines, breast tumors and primary lymphocytes.
Results: We have identified RanBPM as an interacting protein by the yeast two-hybrid assay and
confirmed this interaction in-vitro by co-immunoprecipitation. RT-PCR analysis of RanBPM mRNA
expression in cell lines (n = 13) shows that RanBPM is widely expressed in different cell types and
that expression is higher in tumor than in normal breast epithelial cell lines. RanBPM expression
can also be induced in peripheral blood mononuclear cells by treatment with PHA. RanBPM mRNA
is also frequently expressed in invasive breast carcinomas (n = 64) and a higher psoriasin/RanBPM
ratio is associated with both ER negative (p < 0.0001) and PR negative status (p < 0.001), and
inflammatory cell infiltrates (p < 0.0001) within the tumor.
Conclusions: These findings support the hypothesis that psoriasin may interact with RanBPM and
this may influence both epithelial and stromal cells and thus contribute to breast tumor
progression.
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Background
We have previously identified the psoriasin gene
(S100A7) as highly expressed in pre-invasive breast cancer
and subsequently found that persistent psoriasin expres-
sion in invasive breast cancer is associated with markers of
poor prognosis [1]. The S100 proteins are calcium-bind-
ing proteins that may influence several cellular activities
such as growth, chemotaxis, adhesion and cytoskeletal ac-
tivity [1–3]. The function of psoriasin and its influence in
breast cancer is unknown. However in vitro and in vivo
study of its role in psoriasis [4] and also in breast tumors
[1] suggests that one possible role may be to influence the
inflammatory response as a secreted chemotactic factor.
We [1] and others [5] have also observed nuclear and cy-
toplasmic expression within squamous and breast epithe-
lial cells which raises the possibility of an additional
function within epithelial cells. We therefore sought to
pursue a possible intracellular function by utilizing the
yeast 2-hybrid approach to screen a normal human breast
expression library for intracellular breast epithelial pro-
teins that might interact with psoriasin and that might of-
fer insights into its functional role in breast tumor
progression.
Methods
Yeast two-hybrid library screen
The full-length psoriasin coding sequence was cloned in
frame with the Gal4 DNA Binding Domain (BD) of the
Bait plasmid pGBT9 (Clontech) by PCR. pGBT9-psor was
transformed into Saccharomyces cerevisiae strain KGY37
(supplied by R.D. Gietz) followed by growth on selective
media. Expression of the psoriasin fusion protein was
confirmed by Western Blot (data not shown). A normal
human mammary gland cDNA Prey library (Clontech)
was screened for proteins that potentially interact with
psoriasin. We screened 1.73 × 107 clones (4X the com-
plexity of the library) and 242 colonies were picked to as-
say for expression of the LacZ reporter gene. Clones
showing positive LacZ expression had the library plasmid
isolated to test for the specificity of their interaction with
psoriasin.
Immunoprecipitation
Full-length psoriasin coding sequence cloned into
pcDNA3.1 (InVitrogen), and RanBPM (amino acids 230–
730) cloned into pcDNA4 HisMax (InVitrogen) in-frame
with the N-terminal His-Xpress epitope tag. 35S-Met la-
belled protein was generated using the Wheat Germ TNT
kit for psoriasin and Rabbit Reticulocyte TNT kit for RanB-
PM according to manufacture's protocol (Promega). La-
beled proteins were co-immunoprecipitated in buffer (50
mM Tris-HCl pH 7.5, 137 mM NaCl, 0.05 mM CaCl2,
0.05% Triton X-100) using anti-HisG antibody (InVitro-
gen). Samples were electrophoresed through a 15% Tris-
Tricine polyacrylamide gel as previously described [1].
The gel was then dried and autoradiography to detect la-
beled proteins.
Cell lines and tumor tissue samples
Peripheral blood leucocytes were obtained from five
healthy subjects by venepuncture and cultured as previ-
ously described [6] Breast cancer cell lines were obtained
from the ATCC and were cultured as previously described
[1] in DMEM supplemented with 10% fetal bovine serum,
100 units/ml penicillin, 100 µg/ml streptomycin and L-
Glutamine. MCF10A cells were the kind gift of Dr. Fred
Miller (Wayne State University, Detroit MI). All cells were
grown at 37°C in a humidified atmosphere of 95% air and
5% CO2. Breast tumor cases were selected from the Mani-
toba Breast Tumor Bank (Winnipeg, Manitoba, Canada),
which operates with ethical approval from the University
of Manitoba's Ethics Board and processed previously de-
scribed [7]. Tumors with estrogen and progesterone recep-
tor levels above 3 fmol/mg total protein and 15 fmol/mg
total protein, respectively, were considered ER or PR posi-
tive.
The study cohort comprised 64 invasive carcinomas se-
lected to represent a range of tumor types and on the basis
of high tissue quality, presence of invasive tumor within
>35% of the cross section of the frozen block and minimal
(<5%) normal or in situ epithelial components. The study
group included different invasive tumor types (34 ductal,
13 lobular, and 17 'special type' tumors), and a range of
ER status (19 negative, 45 positive), PR status (30 nega-
tive, 34 positive) and stages (37 node negative, 27 node
positive).
Reverse transcriptase-polymerase chain reaction (RT-
PCR) analysis
RT-PCR was performed on extracted total RNA (200 ng)
that was reverse transcribed as described previously [8].
Real-time Quantitative PCR and analysis was performed
with the Roche LightCycler. Each PCR reaction was per-
formed in a total volume of 20 µl and consisted of 0.2 µl
of each sense and anti-sense primer at 50 µM, 1.6 µl of 25
µM MgCl2, 15 µl H2O, 2 µl Master Mix (LightCycler- DNA
Master SYBR Green I) and l µl cDNA template.
The psoriasin primers were sense (5'-AAG AAA GAT GAG
CAA CAC-3') and antisense (5'-CCA GCA AGG ACA GAA
ACT-3') corresponding to the cDNA sequence. RanBPM
primers were sense (5'-CGC ACA TTT TTC AGG TTT-3')
and antisense (5'-CTT GCC ACA GTC TCT CCT T-3'). Cy-
clophilin 33 was used as a loading control for analysis of
RanBPM in cell lines and PBMCs using sense (5'-GCT
GCG TTC ATT CCT TTT G-3') and antisense (5'-CTC CTG
GGT CTC TGC TTT G-3'). All PCR primers were designed
to span at least one intron-exon boundary to prevent am-
plification of possible genomic DNA contamination. ForBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/28
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PCR amplification in the LightCycler melting curve analy-
sis was preformed at the end of the cycling program to
confirm specificity of amplification. Psoriasin, cyclophilin
33 and RanBPM PCR products were each cloned into
pGEM-T Easy (Promega), sequenced and then serially di-
luted separately to construct the standard curve used for
quantification of mRNA expression.
Tumors from each cohort were processed as a batch, from
frozen sectioning to RNA extraction, reverse transcription
in duplicate and then duplicate PCRs from each RT reac-
tion. Controls included RT- and RNA- controls. RNA from
PBMLs of five subjects were collected from 3 × 106 cells af-
ter 24-hour treatment (10 µg/ml PHA, 0.1 ng/ml TSST-1,
30 ng/ml anti-CD3, 10 ng/ml LPS and SAC stimulation at
0.0025% and 0.00025%) as well as unstimulated cells
grown for 24 hours in media alone. All RNA isolations
were performed using Tri-reagent according to the manu-
facture's directions (Sigma).
Statistical analysis
For statistical analysis, psoriasin and RanBPM mRNA lev-
els and the psoriasin/RanBPM ratio were assessed either as
a continuous variable or transformed into low or high ex-
pression categories using the 75th percentile as a cutpoint
for all variables. This cutpoint was selected as it corre-
sponded to the minimum mRNA level at which psoriasin
protein could be detected by Western blot analysis of fro-
zen sections from a subset of the tumors (Data not
shown). Correlations were tested using Spearman's test
and associations with categorical variables were tested by
Chi-squared test. For induction of RanBPM in PBMC, one-
way ANOVA (nonparametric) analysis was performed on
the means of duplicate Reverse Transcription samples for
selected treatments.
Results
Yeast two-hybrid screen and identification of true positives
The yeast Bait vector pGBT9-psoriasin was used to screen
a normal human mammary gland cDNA expression li-
brary (Clontech) to identify potential proteins with which
psoriasin forms a physical interaction. Clones that grew
on selection media were isolated and examined for the
strength and specificity of their interaction with psoriasin.
Four clones were identified that specifically interacted
with psoriasin in the yeast system. We pursued the inter-
action of RanBPM (clone 6–3) with psoriasin as it present-
ed the strongest interaction, as determined by the
intensity of activation of the reporter gene LacZ (data not
shown). Psoriasin was demonstrated to specifically inter-
act with RanBPM in the yeast system (Figure 1).
Co-immunoprecipitation of psoriasin and RanBPM
Both psoriasin and RanBPM were cloned by PCR into
their respective expression vectors downstream of a T7
promoter and 35S-Met labeled proteins were generated.
Figure 1
Confirmation of specificity of interactions observed
in yeast 2-hybrid assay. Panels show yeast transformed
with a) psoriasin and RanBPM expression plasmids (left) and
RanBPM alone (right), and yeast transformed with b) Psoria-
sin alone, c) psoriasin and empty prey vector, and d) psoria-
sin with a control gene not isolated in the primary screen. In
panels b-d, plates on left are Histidine + (control) and plates
on the right are Histidine – (test). Panel a) shows activation
of LacZ reporter gene only occurs in yeast transformed with
both expression plasmids (left) and no activation in yeast
transformed with RanBPM alone (right). Panel b) shows that
psoriasin alone cannot activate the Histidine reporter gene as
demonstrated by absence of growth on Histidine – plate.
Panels c) and d) show that there is a specific interaction nec-
essary for activation of the reporter gene.
Figure 2
In vitro interaction of psoriasin and RanBPM as deter-
mined by co-immunoprecipitation.35S-Met labelled pro-
teins were generated. Psoriasin (lane 1) and RanBPM (lane 2)
were electrophoresed through a denaturing polyacrylamide
gel and detected by autoradiography. Psoriasin binds to and
co-immunoprecipitates with RanBPM (lane 4). RanBPM and
psoriasin do not bind to protein G-beads on their own, (lane
3 and 5 respectively). RanBPM does not interact with mouse
submaxillary gland protein when either RanBPM (lane 6) or
mouse submaxillary gland protein (lane 7) is precipitated.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/28
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The radiolabelled proteins were immunoprecipitated by
addition of anti-HisG antibody, which specifically detects
the His-tagged RanBPM protein. As shown (Figure 2), the
protein-protein interaction observed in yeast was con-
firmed by these co-immunoprecipitation studies.
Cell line expression
RanBPM mRNA expression was assessed by RT-PCR in es-
tablished fibroblast and epithelial cell lines and in freshly
obtained peripheral blood mononuclear cells (Figure 3).
RanBPM was detected in all cells and the relative levels
differed between cell types. Amongst the established cell
lines there was no significant difference between fibrob-
lasts, normal epithelial cells and Ras-transformed deriva-
tives of the same normal epithelial cell. RanBPM
expression was consistently higher in tumor cell lines
compared to normal cells (p = 0.0007), with up to a 3-fold
difference in levels. Within the set of 5 breast tumor cell
lines examined, no relationship with ER status or epithe-
lial differentiation was evident. Psoriasin expression was
undetectable or very low in all cell lines (data not shown).
RanBPM expression was also examined in primary cul-
tures of peripheral blood mononuclear cells. In experi-
ments with samples from 5 healthy subjects, RanBPM
mRNA was strongly induced in cells following 24-hour
stimulation with the polyclonal activator PHA (p <
0.001). PHA elicits dominantly Th2 associated cytokine
response [6]. In contrast, cells stimulated by polyclonal
activators that elicit Th1 dominated immunity (anti-CD3,
TSST-1) or cytokine production by antigen presenting
cells that is Th1 inducing (LPS, SAC), an increase in RanB-
PM expression was weak to undetectable (Figure 4). No
significant differences were apparent in RanBPM expres-
sion between male (n = 3) and female (n = 2) subjects in
this sample.
Figure 3
RanBPM mRNA expression in selected cell lines. RanBPM mRNA expression in fibroblasts (CRL and 125), normal mam-
mary epithelia (MCF10ATB, MCF10A1, MCF10AT1), and epithelial carcinoma cell lines from breast (T47D5, MCF-7, 126,
MDA-MB-231, BT20) and cervix (HeLa). RanBPM is expressed at higher levels in cells derived from tumors compared to those
derived from normal epithelia and stroma. Columns and bars represent means and standard deviations from duplicate experi-
ments. Mann Whitney test was used to compare levels between normal epithelial cells and fibroblasts (*) or neoplastic epithe-
lial cells (**).BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/28
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Tumor expression
The relationship between RanBPM, psoriasin, the psoria-
sin/RanBPM ratio and indicators of differentiation and
prognosis was examined in a series of 64 invasive breast
tumors by quantitative RT-PCR (Table 1). Higher levels of
expression of either RanBPM or psoriasin were present in
only 16/64 and 16/64 tumors respectively, however high
levels of expression of both genes was observed to coin-
cide in 4/64 cases. This small subset of cases showed no
significant distinguishing clinical features. Higher RanB-
PM mRNA levels were seen in association with ER positive
status and low inflammation. However there was no sig-
nificant difference in RanBPM mRNA expression with any
parameter including indicators of differentiation (ER, PR,
tumor type or grade) or stage (tumor size and nodal sta-
tus) or with cellular composition of the tumor section (in-
flammation and proportion of epithelial tumor cells and
stroma). At the same time higher levels of psoriasin ex-
pression were significantly associated with ER negative
and PR negative status and inflammation (Table 1). The
psoriasin/RanBPM ratio showed even stronger and highly
significant associations with the same three parameters,
and it was also higher in medullary carcinomas compared
to other special type tumors (mucinous and tubular), lob-
ular, and ductal carcinomas (p = 0.0313).
Discussion
To pursue the role of psoriasin (S100A7) expression in
breast cancer we sought interacting proteins in breast epi-
thelial cells using the yeast 2-hybrid assay. We have iden-
tified RanBPM as a potential interacting protein and
confirmed this interaction by in vitro assay. Study of cell
lines and breast tumors shows that RanBPM mRNA is
widely expressed and that while RanBPM expression
shows no specific relationship with markers of differenti-
ation or prognosis, high levels of expression of both genes
is present in some tumors, and a strong association exists
between the psoriasin/RanBPM ratio and both ER/PR sta-
tus and inflammatory cell infiltrates within the tumor.
The biological role of psoriasin in breast tumors is not
known, however it may be related to aspects of tumor pro-
gression. This role might be mediated either through an
indirect influence on the host immune response or
through a more direct influence on the epithelial tumor
cell. The first hypothesis is supported by correlations be-
tween psoriasin and the intensity of the host inflammato-
ry cell response within invasive breast tumors [1] and in
vitro effects as a secreted chemotactic factor for T-cells [4].
The second hypothesis is supported by evidence that pso-
riasin may not only be secreted [9,10]. but also can be lo-
calized in both nuclear and cytoplasmic epithelial cell
compartments in normal skin and breast tumors [1]. Oth-
er secreted S100 proteins have also been localized to cyto-
plasm and nucleus [11] and altered subcellular
localization in disease has also been observed with a ke-
ratinocyte S100 related protein, profilaggrin [12,13].
RanBPM was originally described as a Ran binding pro-
tein that is highly conserved between human, mouse and
hamster, and detectable in both skin fibroblast and HeLa
cell lines [14]. However, more recently it has been found
that the original study had centered on a N-terminally
truncated cDNA and that the full size RanBPM cDNA en-
codes a larger 90 kDa protein that localizes to both the nu-
cleus and also to the peri-nuclear and peri-centrosomal
cytoplasmic region in HeLa cells [15]. While RanBPM was
identified through its ability to interact with the Ran nu-
clear-cytoplasmic transport protein in the yeast system,
when overexpressed the c-terminal portion of RanBPM
was capable of causing reorganization of the microtubule
network and ectopic nucleation of microtubules in vivo,
and this effect could also be inhibited by GTP-Ran [14].
This is of interest as although Ran is known to play a key
role in nuclear transport [16,17], it has also been associat-
ed with a variety of additional functions, including cell
proliferation and viability in breast cells [18] that may be
mediated by interactions with a number of Ran binding
proteins. While the full length RanBPM has now been
identified, the exact role for this protein in microtubule
function remains to be explored. Our findings here con-
firm that RanBPM is expressed in multiple cell types and
show that it may be increased in breast tumor cell lines. In
breast tumors higher levels of expression of RanBPM and
psoriasin overlapped in some cases. While this small sub-
Figure 4
RanBPM mRNA expression in peripheral blood
mononuclear cells (PBMCs). RanBPM mRNA expression
is strongly induced by stimulation of cells with PHA, weakly
induced by TSST-1, but not anti-CD3, LPS or SAC. Columns
and bars represent means and standard deviations from
duplicate experiments performed on samples from 5 donors.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/28
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set of cases showed no significant distinguishing clinical
features and there was no association with known prog-
nostic factors, the expression of RanBPM was inversely re-
lated to psoriasin. There was also a tendency to higher
levels of RanBPM in association with ER positivity and
low levels of inflammation, leading to highly significant
differences in the psoriasin/RanBPM ratio in tumors that
differed by ER status and extent of inflammation. This lat-
ter association is also supported by the higher psoriasin/
RanBPM ratio found in medullary carcinomas compared
to other invasive tumors, where higher levels of inflam-
mation are inherent in the diagnosis of this special tumor
type. Our data also suggests that RanBPM is rapidly ex-
pressed by primary PBMC, in particular upon stimulation
leading to type-2 immunity. This raises the possibility that
RanBPM could be a target for mediating the actions of se-
creted psoriasin, perhaps affecting T cell trafficking to ac-
tivated or inflamed sites.
Psoriasin has also been found to interact with two other
proteins. It is a substrate for transglutaminases TG1 and
TG2 [19], and a binding partner for epidermal fatty acid
binding protein (E-FABP) in epidermis [5]. Transglutami-
nases are expressed in both epithelium and inflammatory
cells and their cross linking capacity is associated with a
range of functions including apoptosis and terminal dif-
ferentiation in keratinocytes, cross linking of extracellular
matrix proteins, and interaction with integrins to mediate
adhesion and motility of monocytic cells [20]. The FABP
proteins have also been implicated in terminal differenti-
ation in both epidermis and breast epithelium where
overexpression of H-FABP and B-FABP can both cause
Table 1: Relationship Between RanBPM and Psoriasin Expression and Clinical-Pathological Parameters in Human Breast Cancer
Ran BPM Psoriasin Psoriasin/RanBPM
low high p value low high p value low high p value
ER -ve 16 3 ns 8 11 0.0002 7 12 <0.0001
+ve 32 13 40 5 41 4
PR -ve 23 7 ns 17 13 0.001 17 13 0.002
+ve 25 9 35 3 31 3
INFL low 36 15 ns 41 10 0.049 44 7 <0.0001
high 12 1 15 6 4 9
NS neg 28 9 ns 30 7 ns 27 10 ns
pos 20 7 18 9 21 6
GRADE low 14 3 ns 15 2 ns 15 4 ns
int 13 5 12 6 13 5
high 9 3 9 3 8 4
SIZE < = 2 11 5 ns 10 3 ns 11 5 ns
>2 27 12 32 11 32 7
TYPE ductal 26 9 26 9 25 9
lobular 11 2 11 2 11 2
mucinous 3 3 4 1 5 1
tubular 4 2 4 2 5 1
medullary 5 0 3 2 1 4BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/28
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growth inhibition and reduction of tumorigencity in
mammary carcinoma cells. In the CNS, B-FABP has also
been implicated in the control of the glial fibre system and
neuronal migration. RanBPM is a third interacting pro-
tein, that is expressed in several cell types, is induced in
PHA stimulated peripheral blood leucocytes, and when
overexpressed as a truncated protein can affect microtu-
bule function. The interaction with psoriasin may just re-
flect a common mode of intracellular transport. However,
one common functional association to these three inter-
acting proteins is an involvement in cytoskeletal func-
tions, adhesion, and migration. Alterations of adhesion
and polarity are associated with the progression of breast
cancer and are inherent in the process of invasion. While
psoriasin expression in keratinocytes [21] is associated
with changes in adhesion, it remains to be determined if
manipulation of psoriasin in squamous and breast epithe-
lial cells can directly influence cell adhesion.
In conclusion, we have shown that psoriasin interacts
with an intracellular protein, RanBPM in-vitro. Further
study to confirm the interaction in-vivo and explore the
biological role of RanBPM in breast and inflammatory
cells may help to elucidate the role of psoriasin in breast
cancer.
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